A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe
A Mocroft, P Reiss, A Rakhmanova, D Banhegyi, A N Phillips, S De Wit, M Ristola, J D Lundgren, J Grarup, O Kirk, EuroSIDA in EuroCOORD, M Losso, M Kundro, N Vetter, R Zangerle, I Karpov, A Vassilenko, V M Mitsura, O Suetnov, S De Wit, M Delforge, R Colebunders, L Vandekerckhove, V Hadziosmanovic, K Kostov, J Begovac, L Machala, D Jilich, D Sedlacek, J Nielsen, G Kronborg, T Benfield, M Larsen, J Gerstoft, T Katzenstein, A-B E Hansen, P Skinhøj, C Pedersen, L Ostergaard, K Zilmer, M Ristola, C Katlama, J-P Viard, P-M Girard, J M Livrozet, P Vanhems, C Pradier, F Dabis, D Neau, J Rockstroh, R Schmidt, J van Lunzen, O Degen, H J Stellbrink, M M Bickel, J W Goethe, J Bogner, G Fätkenheuer, J Kosmidis, P Gargalianos, G Xylomenos, J Perdios, G Panos, A Filandras, E Karabatsaki, H Sambatakou, D Banhegyi, F Mulcahy, I Yust, D Turner, S Pollack, G Hassoun, S Maayan, S Vella, R Esposito, I Mazeu, C Mussini, C Arici, R Pristera, F Mazzotta, A Gabbuti, V Vullo, M Lichtner, A Chirianni, E Montesarchio, M Gargiulo, A D Cotugno, G Antonucci, A Testa, G D'Offizi, C Vlassi, M Zaccarelli, A Antorini, A Lazzarin, A Castagna, N Gianotti, M Galli, A Ridolfo, L Sacco, B Rozentale, I Zeltina, S Chaplinskas, T Staub, R Hemmer, P Reiss, V Ormaasen, A Maeland, J Bruun, B Knysz, J Gasiorowski, A Horban, E Bakowska, A Grzeszczuk, R Flisiak, A Boron-Kaczmarska, M Pynka, M Parczewski, M Beniowski, E Mularska, H Trocha, E Jablonowska, E Malolepsza, K Wojcik, F Antunes, M Doroana, L Caldeira, K Mansinho, F Maltez, D Duiculescu, Victor Babes, A Rakhmanova, N Zakharova, S Buzunova, D Jevtovic, M Mokráš, D Staneková, J Tomazic, J González-Lahoz, V Soriano, P Labarga, J Medrano, S Moreno, J M Rodriguez, B Clotet, A Jou, R Paredes, C Tural, J Puig, I Bravo, J M Gatell, J M Miro, P Domingo, M Gutierrez, G Mateo, M A Sambeat, A Blaxhult, L Flamholc, A Thalme, A Sonnerborg, B Ledergerber, R Weber, P Francioli, M Cavassini, B Hirschel, E Boffi, H Furrer, M Battegay, L Elzi, E Kravchenko, N Chentsova, V Frolov, G Kutsyna, S Servitskiy, M Krasnov, S Barton, A M Johnson, D Mercey, A Phillips, M A Johnson, A Mocroft, M Murphy, J Weber, G Scullard, M Fisher, C Leen, J Gatell, B Gazzard, A Horban, I Karpov, B Ledergerber, M Losso, A D'Arminio Monforte, C Pedersen, A Rakhmanova, M Ristola, J Rockstroh, S De Wit, J Lundgren, A Phillips, P Reiss, O Kirk, A Mocroft, A Cozzi-Lepri, D Grint, A Schultze, L Shepherd, M Sabin, D Podlekareva, J Kjær, L Peters, J Nielsen, J Tverland, A H Fischer, O Kirk, A Mocroft, J Grarup, P Reiss, A Cozzi-Lepri, R Thiebaut, J Rockstroh, D Burger, R Paredes, J Kjær, L Peters, A Mocroft, P Reiss, A Rakhmanova, D Banhegyi, A N Phillips, S De Wit, M Ristola, J D Lundgren, J Grarup, O Kirk, EuroSIDA in EuroCOORD, M Losso, M Kundro, N Vetter, R Zangerle, I Karpov, A Vassilenko, V M Mitsura, O Suetnov, S De Wit, M Delforge, R Colebunders, L Vandekerckhove, V Hadziosmanovic, K Kostov, J Begovac, L Machala, D Jilich, D Sedlacek, J Nielsen, G Kronborg, T Benfield, M Larsen, J Gerstoft, T Katzenstein, A-B E Hansen, P Skinhøj, C Pedersen, L Ostergaard, K Zilmer, M Ristola, C Katlama, J-P Viard, P-M Girard, J M Livrozet, P Vanhems, C Pradier, F Dabis, D Neau, J Rockstroh, R Schmidt, J van Lunzen, O Degen, H J Stellbrink, M M Bickel, J W Goethe, J Bogner, G Fätkenheuer, J Kosmidis, P Gargalianos, G Xylomenos, J Perdios, G Panos, A Filandras, E Karabatsaki, H Sambatakou, D Banhegyi, F Mulcahy, I Yust, D Turner, S Pollack, G Hassoun, S Maayan, S Vella, R Esposito, I Mazeu, C Mussini, C Arici, R Pristera, F Mazzotta, A Gabbuti, V Vullo, M Lichtner, A Chirianni, E Montesarchio, M Gargiulo, A D Cotugno, G Antonucci, A Testa, G D'Offizi, C Vlassi, M Zaccarelli, A Antorini, A Lazzarin, A Castagna, N Gianotti, M Galli, A Ridolfo, L Sacco, B Rozentale, I Zeltina, S Chaplinskas, T Staub, R Hemmer, P Reiss, V Ormaasen, A Maeland, J Bruun, B Knysz, J Gasiorowski, A Horban, E Bakowska, A Grzeszczuk, R Flisiak, A Boron-Kaczmarska, M Pynka, M Parczewski, M Beniowski, E Mularska, H Trocha, E Jablonowska, E Malolepsza, K Wojcik, F Antunes, M Doroana, L Caldeira, K Mansinho, F Maltez, D Duiculescu, Victor Babes, A Rakhmanova, N Zakharova, S Buzunova, D Jevtovic, M Mokráš, D Staneková, J Tomazic, J González-Lahoz, V Soriano, P Labarga, J Medrano, S Moreno, J M Rodriguez, B Clotet, A Jou, R Paredes, C Tural, J Puig, I Bravo, J M Gatell, J M Miro, P Domingo, M Gutierrez, G Mateo, M A Sambeat, A Blaxhult, L Flamholc, A Thalme, A Sonnerborg, B Ledergerber, R Weber, P Francioli, M Cavassini, B Hirschel, E Boffi, H Furrer, M Battegay, L Elzi, E Kravchenko, N Chentsova, V Frolov, G Kutsyna, S Servitskiy, M Krasnov, S Barton, A M Johnson, D Mercey, A Phillips, M A Johnson, A Mocroft, M Murphy, J Weber, G Scullard, M Fisher, C Leen, J Gatell, B Gazzard, A Horban, I Karpov, B Ledergerber, M Losso, A D'Arminio Monforte, C Pedersen, A Rakhmanova, M Ristola, J Rockstroh, S De Wit, J Lundgren, A Phillips, P Reiss, O Kirk, A Mocroft, A Cozzi-Lepri, D Grint, A Schultze, L Shepherd, M Sabin, D Podlekareva, J Kjær, L Peters, J Nielsen, J Tverland, A H Fischer, O Kirk, A Mocroft, J Grarup, P Reiss, A Cozzi-Lepri, R Thiebaut, J Rockstroh, D Burger, R Paredes, J Kjær, L Peters
Abstract
ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥ 3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.
Figures
References
- Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51:163–174. doi: 10.1097/QAI.0b013e3181a572cf.
- Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2009;51:562–568. doi: 10.1097/QAI.0b013e3181ae2eb9.
- European Medicines Agency. Atripla. Efavirenz/emtricitabine/tenofovir disoproxil, EPAR summary for the public. 2013. . Accessed 18 Mar 2013.
- European Medicines Agency. Tenofovir. EPAR summary for the public. 2013. . Accessed 19 Sept 2013.
- Bannister WP, Kirk O, Gatell JM, Knysz B, Viard JP, Mens H, et al. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr. 2006;42:229–237. doi: 10.1097/01.qai.0000214815.95786.31.
- World Health organisation. 2013. Antiretroviral therapy for HIV infection in adults and adolescents.
- EACS European AIDS Clinical Society Guidelines. 2013. Version 6.1 November 2012.
- AIDSinfo. 2012. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. .
- Sax PE, Dejesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439–2448. doi: 10.1016/S0140-6736(12)60917-9.
- Zolopa A, Sax PE, Dejesus E, Mills A, Cohen C, Wohl D, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63:96–100. doi: 10.1097/QAI.0b013e318289545c.
Source: PubMed